Streetbeat News

Analyst Ratings

IKT

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Inhibikase Therapeutics (NASDAQ:IKT) and maintained a price target of $27.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:51 pm

CYBN

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Cybin (AMEX:CYBN) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:50 pm

MNDY

Citigroup analyst Steven Enders maintains a Buy rating on Monday.Com (NASDAQ:MNDY) and raises the price target from $224 to $234.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:47 pm

VIRX

RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viracta Therapeutics (NASDAQ:VIRX), maintaining a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:47 pm

NICE

Citigroup analyst Tyler Radke maintains a Buy rating on NICE (NASDAQ:NICE) and raises the price target from $278 to $338.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:46 pm

SPRB

RBC Capital analyst Gregory Renza has reiterated an 'Outperform' rating on Spruce Biosciences (NASDAQ:SPRB), maintaining a price target of $8.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:45 pm

UPXI

Alliance Global Partners analyst Aaron Grey has maintained a 'Buy' rating on Upexi (NASDAQ:UPXI) but lowered the price target from $7 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:44 pm

SCTL

RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Societal CDMO (NASDAQ:SCTL) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 3:44 pm

NVTA

Piper Sandler analyst David Westenberg has maintained an Underweight rating on Invitae (NYSE:NVTA) and lowered the price target from $1.5 to $0.5.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:40 pm

TSVT

Guggenheim analyst Kelsey Goodwin has maintained a 'Buy' rating on 2seventy bio (NASDAQ:TSVT), but lowered the price target from $27 to $26.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 3:34 pm